Conivaptan: A selective vasopressin antagonist

Drugs of Today

Volumn 42, Issue 6, 2006, Pages 379-386

  Sulemanjee, Nasir Z ^a   Schwarz, Ernst R ^a,b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CONIVAPTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; WARFARIN;

ADRENERGIC SYSTEM; BINDING AFFINITY; BINDING SITE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORTICOTROPIN RELEASE; DIABETES INSIPIDUS; DIARRHEA; DIESTRUS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; FEMALE INFERTILITY; FETUS GROWTH; GLUCAGON RELEASE; HEADACHE; HEART FAILURE; HEART MUSCLE CELL; HOMEOSTASIS; HUMAN; HYPERTROPHY; HYPOKALEMIA; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INFLAMMATION; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PERIPHERAL EDEMA; PHLEBITIS; POLLAKISURIA; REVIEW; SIDE EFFECT; THIRST; VASCULAR SMOOTH MUSCLE; VOMITING;

ANIMALS; BENZAZEPINES; CLINICAL TRIALS; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; PREGNANCY; RECEPTORS, VASOPRESSIN;

EID: 33746225240     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.6.985639     Document Type: Review

References (35)

1. Schrier, R.W., Abraham, W.T. Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341: 577-85.
2. Kamoi, K., Ishibashi, M., Yamaji, T. Interaction of osmotic and nonosmotic stimuli in regulation of vasopressin secretion in hypo-osmolar state of man. Endocr J 1997, 44: 311-7.
3. Reilly, B.A., Brostrom, M.A., Brostrom, C.O. et al. Regulation of protein synthesis in ventricular myocytes by vasopressin. The role of sarcoplasmic/endoplasic reticulum Ca2+ stores. J Biol Chem 1998, 273: 3747-55.
4. Chandrashekhar, Y., Prahash, A.J., Sen, S. et al. The role of arginine vasopressin and its receptors in the normal and failing rat heart. J Mol Cell Cardiol 2003, 35: 495-504.
5. Abraham, W.T., Schrier, R.W. Body fluid volume regulation in health and disease. Adv Intern Med 1994, 39: 23-47.
6. Chatterjee, K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 2005, 95: 8B-13.
7. Uretsky, B.F., Verbalis, J.G., Generalovich, T. et al. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol 1985, 248: H396-401.
8. Goldsmith, S.R., Francis, G.S., Cowley, A.W. et al. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986, 8: 779-83.
9. Sanghi, P., Uretsky, B.F., Schwarz, E.R. Vasopressin antagonism: A future treatment option in heart failure. Eur Heart J 2005, 26: 538-43.
10. Golestaneh, L., Talreja, A., Le Jemtel, T.H. Vasopressin antagonists in heart failure. Curr Heart Fail Rep 2004, 1: 190-6.
11. Lee, C.R., Watkins, M.L., Patterson, J.H. et al. Vasopressin: A new target for the treatment of heart failure. Am Heart J 2003, 146: 9-18.
12. Doggrell, S.A. Conivaptan Yamanouchi. Curr Opin Investig Drugs 2005, 6: 317-26.
13. Schwarz, E.R., Sanghi, P. Conivaptan: A selective vasopressin antagonist for the treatment of heart failure. Expert Rev Cardiovasc Ther 2006, 4: 17-23.
14. Tahara, A., Saito, M., Sugimoto, T. et al. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol 1998, 125: 1463-70.
15. Walker, B.R., Childs, M.E., Adams, E.M. Direct cardiac effects of vasopressin: Role of V1- and V2-vasopressinergic receptors. Am J Physiol 1988, 255: H261-5.
16. Park, F., Mattson, D.L., Skelton, M.M., Cowley, A.W. Jr. Localization of the vasopressin Via and V2 receptors within the renal cortical and medullary circulation. Am J Physiol 1997, 273: R243-51.
17. Wallace, A.W., Tunin, C.M., Shoukas, A.A. Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol 1989, 257: H1228-34.
18. Khayyal, M.A., Eng, C., Franzen, D., Breall, J.A., Kirk, E.S. Effects of vasopressin on the coronary circulation: Reserve and regulation during ischemia. Am J Physiol 1985, 248: H516-22.
19. Ebert, T.J., Cowley, A.W. Jr., Skelton, M. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. J Clin Invest 1986, 77: 1136-42.
20. Ebert, T.J., Cowley, A.W. Jr. Baroreflex modulation of sympathetic outflow during physiological increases of vasopressin in humans. Am J Physiol 1992, 262: H1372-8.
21. Tahara, A., Tomura, Y., Wada, K. et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J Cardiovasc Pharmacol 1997, 30: 759-66.
22. Yatsu, T., Tomura, Y., Tahara, A. et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 1999, 376: 239-46.
23. Tahara, A., Tomura, Y., Wada, K. et al. Binding characteristics of YM087, an AVP receptor antagonist, in rhesus monkey liver and kidney membranes. Peptides 1998, 19: 691-6.
24. Tahara, A., Tomura, Y., Wada, K.I. et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1997, 282: 301-8.
25. Burnier, M., Fricker, A.F., Hayoz, D., Nussberger, J., Brunner, H.R. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 1999, 55: 633-7.
26. Tahara, A., Tsukada, J., Tomura, Y. et al. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res 2005, 51: 275-81.
27. Yatsu, T., Tomura, Y., Tahara, A. et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. Eur J Pharmacol 1997, 321: 225-30.
28. Tahara, A., Tomura, Y., Wada, K. et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998, 38: 198-205.
29. Wada, K., Tahara, A., Arai, Y. et al. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. Eur J Pharmacol 2002, 450: 169-77.
30. Wada, K., Fujimori, A., Matsukawa, U. et al. Administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol 2005, 507: 145-51.
31. Naitoh, M., Risvanis, J., Balding, L.C., Johnston, C.I., Burrell, L.M. Neurohormonal antagonism in heart failure, beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. Cardiovasc Res 2002, 54: 51-7.
32. Ghali, J.K., Koren, M.J., Taylor, J.R. et al. Efficacy and safety of oral conivaptan: A V1A/V2 vasopressin-receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006.
33. Udelson, J.E., Smith, W.B., Hendrix, G.H. et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001, 104: 2417-23.
34. Russell, S.D., Selaru, P., Pyne, D.A. et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose Evaluation of a Vasopressin Antagonist in CHF Patients Undergoing Exercise) trial. Am Heart J 2003, 145: 179-86.
35. Gheorghiade, M., Orlandi, C., Burnett, J.C. et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005, 11: 260-9.